Download PDF

1. Company Snapshot

1.a. Company Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines.The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd.


for the development and commercialization of tamibarotene.The company was formerly known as LS22, Inc.and changed its name to Syros Pharmaceuticals, Inc.


in August 2012.Syros Pharmaceuticals, Inc.was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on SYRS

Syros Pharmaceuticals' recent struggles are attributed to its voluntary delisting from Nasdaq and SEC deregistration, which may signal a lack of confidence in the company's future prospects. This move will terminate and suspend the company's reporting obligations, reducing transparency and potentially limiting access to capital markets. The decision may also raise concerns about the company's financial health and ability to meet its obligations.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

Feb -28

Source: businesswire.com

Card image cap

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Nov -14

Source: zacks.com

Card image cap

Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default

Nov -13

Source: benzinga.com

Card image cap

The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions

Nov -04

Source: accesswire.com

Card image cap

Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

Nov -03

Source: accesswire.com

Card image cap

The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations

Nov -02

Source: accesswire.com

Card image cap

Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript

Oct -31

Source: seekingalpha.com

Card image cap

Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm

Oct -27

Source: accesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Gene Control Medicines

Expected Growth: 11.3%

Syros Pharmaceuticals' Gene Control Medicines segment growth of 11.3% is driven by increasing adoption of precision medicine, rising prevalence of genetic disorders, and advancements in gene editing technologies such as CRISPR. Additionally, growing investments in R&D and strategic partnerships are expanding the company's pipeline and accelerating product development.

7. Detailed Products

SY-1424

A selective inhibitor of the cyclin-dependent kinase 7 (CDK7) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

SY-5609

A selective inhibitor of the cyclin-dependent kinase 7 (CDK7) for the treatment of solid tumors

SY-2101

A selective inhibitor of the cyclin-dependent kinase 12/13 (CDK12/13) for the treatment of hematological malignancies

8. Syros Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Syros Pharmaceuticals, Inc. operates in a highly competitive industry, and there are many substitutes available for its products. However, the company's focus on developing novel therapies and its strong research and development capabilities help to mitigate the threat of substitutes.

Bargaining Power Of Customers

Syros Pharmaceuticals, Inc. has a diverse customer base, and no single customer accounts for a significant portion of its revenue. This reduces the bargaining power of customers.

Bargaining Power Of Suppliers

Syros Pharmaceuticals, Inc. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size and reputation, suppliers still have some negotiating power.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market. Syros Pharmaceuticals, Inc. needs to continuously innovate and invest in research and development to stay ahead of new entrants.

Intensity Of Rivalry

The biotechnology industry is highly competitive, and Syros Pharmaceuticals, Inc. faces intense rivalry from established players and new entrants. The company needs to focus on differentiating its products and services to gain a competitive advantage.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 72.33%
Debt Cost 8.26%
Equity Weight 27.67%
Equity Cost 12.64%
WACC 9.47%
Leverage 261.36%

11. Quality Control: Syros Pharmaceuticals, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Xeris Biopharma

A-Score: 5.2/10

Value: 6.2

Growth: 7.1

Quality: 5.4

Yield: 0.0

Momentum: 10.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Dianthus Therapeutics

A-Score: 4.6/10

Value: 6.4

Growth: 6.0

Quality: 5.0

Yield: 0.0

Momentum: 8.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
MannKind

A-Score: 4.0/10

Value: 3.2

Growth: 8.7

Quality: 7.1

Yield: 0.0

Momentum: 2.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Kymera Therapeutics

A-Score: 3.8/10

Value: 6.4

Growth: 3.1

Quality: 4.9

Yield: 0.0

Momentum: 6.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Syros Pharmaceuticals

A-Score: 3.5/10

Value: 8.2

Growth: 5.6

Quality: 7.4

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
OmniAb

A-Score: 2.7/10

Value: 7.7

Growth: 1.6

Quality: 4.6

Yield: 0.0

Momentum: 0.0

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.0$

Current Price

0.0$

Potential

-0.00%

Expected Cash-Flows